February 15, 2023 Spotlight – still plenty of hopefuls in lung fibrosis Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
February 11, 2021 Gilead’s Galapagos hopes now rest on Toledo Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.